ClinicalTrials.gg
Enrolling by invitationNCT05677386Updated Nov 5, 2026

The DANE-HEART Trial - Computed Tomography Coronary Angiography for Primary Prevention

An interventional study of Primary preventive treatment guided by CTCA and Cardiovascular risk Score in Coronary Atherosclerosis and Other Heart Disease and Cardiovascular Diseases, sponsored by Copenhagen University Hospital, Rigshospitalet. Enrolling by invitation at 2 sites in Denmark. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Copenhagen University Hospital, Rigshospitalet · Not applicable, Interventional, and Prevention

How we know

Updated Nov 5, 2026Primary completion movedSponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6,000
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 184 studies in Coronary Artery Disease with a site in Denmark — 23 open to participants now, 44 under way, 5 of them phase 3. Coronary Artery Disease · Denmark.

Planned enrollment
11th of 136
6,000 · median 455
Started
2023
with 7 others
No phase
88 of 184
16 open now
Primary completion
2027-12
later than 25 of 43 live
Registered
163rd of 184
by date

Among the 184 studies in Coronary Artery Disease with a site in Denmark, this one is the 11th largest by planned enrollment of the 136 interventional ones that give a count, is one of 8 that started in 2023, is one of 88 with no phase, reaches primary completion later than 25 of the 43 other live ones, and was the 163rd registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

23 of the 184 studies in Coronary Artery Disease with a site in Denmark are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Coronary Artery Disease with a site in Denmark, or all of them as a file.
02

Study summary

The goal of this randomized controlled clinical trial in asymptomatic individuals with risk factors for cardiovascular disease is to investigate whether a preventive treatment strategy guided by computed tomography coronary angiography (CTCA) provides a patient-centered approach, which ensures optimal protection against serious cardiovascular disease.

The main question it aims to answer is:

Does preventive treatment guided by CTCA reduce the risk of heart attacks or cardiovascular death as compared to using conventional cardiovascular risk scores.

Participants will be randomized to preventive medical therapy and/or invasive intervention guided by either CTCA (intervention group) or Systematic COronary Risk Evaluation (SCORE) 2 model for cardiovascular risk prediction (control group).

Read the detailed description

The following hypothesis will be tested:

Primary hypothesis: Primary preventive treatment guided by CTCA reduces the risk of myocardial infarction and cardiovascular death compared to standard care in individuals with risk factors for cardiovascular disease.

Additional objectives that will be addressed in the trial include the impact of a CTCA guided preventive treatment strategy compared to standard care with regards to quality of life, adherence to pharmacological preventive therapy, frequency of invasive diagnostic and therapeutic cardiovascular procedures in addition to health economic assessment of cost-effectiveness.

Trial Design

The DANE-HEART Trial is an investigator-initiated, prospective, open label, parallel group, randomized controlled trial assessing the effect of a CTCA guided preventive treatment strategy. Consecutive individuals at risk of cardiovascular disease will be included and randomized 1:1 to the following strategies

Intervention group: Primary preventive treatment guided by CTCA

Control group: Primary preventive treatment guided by Systematic COronary Risk Evaluation (SCORE) 2 risk assessment model according to Danish clinical guidelines.

Patient Cohort

Individuals participating in the Copenhagen General Population Study will be offered participation in the trial. A total of 8000 individuals will be included, or when 6000 individuals have been randomized.

03

Conditions studied

  • Coronary Atherosclerosis and Other Heart Disease
  • Cardiovascular Diseases

Keywords

  • cardiovascular disease
  • myocardial infarction
  • CT scans
  • heart attack
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Individuals participating in the Copenhagen General Population Study 40 years of age and older, with an estimate (eGFR) ≥30 mL/min/1.73 m2 will be offered participation in the trial.

Inclusion criteria

Inclusion Criteria:

Patients must have at least one of the following cardiovascular risk factors:

  1. >60 years of age
  2. Family history of premature cardiovascular disease (first degree relative with atherosclerotic cardiovascular disease below 60 years)
  3. Hypertension (medically treated, or by clinical assessment)
  4. Diabetes mellitus
  5. Current or recent (within 12 months) smoker
  6. Known hypercholesterolaemia (total cholesterol >6.0 mmol/L or receiving statin therapy)
  7. Rheumatoid arthritis
  8. Systemic lupus erythematosus
  9. Chronic kidney disease stage 3 (estimate glomerular filtration rate 30-59 mL/min/1.73 m2).

Exclusion criteria

Exclusion Criteria:

  1. CTCA related factors

    • Known persistent atrial fibrillation
    • Known x-ray contrast allergy
    • Implanted intracardiac metal devices
  2. Known coronary heart disease or other major atherosclerotic cardiovascular disease

    • Previous coronary revascularization
    • Previous myocardial infarction
    • Heart failure
    • Stroke /
    • Peripheral arterial disease
  3. Prior invasive or non-invasive coronary angiography within the last 5 years
  4. Known homozygous familial hypercholesterolaemia or other serious inherited disorders of lipid metabolism requiring statin therapy
  5. Intolerance of all statins
  6. Statin therapy for >2 years
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
6,000 participants (estimated)

Study arms

  • Active comparator
    Intervention group

    Primary preventive treatment guided by CTCA

    Diagnostic Test: Primary preventive treatment guided by CTCA

  • Sham comparator
    Control group

    Primary preventive treatment guided by Systematic COronary Risk Evaluation (SCORE) 2 model risk assessment according to Danish clinical guidelines.

    Other: Cardiovascular risk Score

Interventions

  • Diagnostic testPrimary preventive treatment guided by CTCA

    Computed tomography coronary angiography (CTCA)

    Also known as: Wide volume CT

  • OtherCardiovascular risk Score

    Systematic COronary Risk Evaluation 2 model for cardiovascular risk prediction

    Also known as: SCORE 2

06

What researchers measure

Primary outcomes

  1. Cardiovascular death or non-fatal acute myocardial infarction

    A composite of cardiovascular death or non-fatal acute myocardial infarction

    Time frame: 5 years

Secondary outcomes

  1. Acute myocardial infarction

    Number of participants with acute myocardial infarction

    Time frame: 5 years

  2. Heart failure

    Number of participants with heart failure

    Time frame: 5 years

  3. Stroke

    Number of participants with stroke

    Time frame: 5 years

  4. Acute aortic event

    Number of participants with acute aortic event

    Time frame: 5 years

  5. Cardiovascular Events

    Number of participants who have fatal and non-fatal myocardial infarction or stroke

    Time frame: 5 years

  6. Death

    Number of all-cause deaths

    Time frame: 5 years

  7. Coronary cardiovascular procedures

    Number of Invasive coronary angiography and coronary revascularisation procedures

    Time frame: 5 years

  8. Aortic cardiovascular procedures

    Number of percutaneous or surgical treatment of aortic disease

    Time frame: 5 years

  9. Aortic valve procedures

    Number of percutaneous or surgical treatments of aortic valve disease

    Time frame: 5 years

  10. Quality of Life (EQ-5D-5L)

    Instrument for Quality of life assessment: Euro Quality of Life - 5 Domain 5 Level (EQ-5D-5L). Value range: 0-100

    Time frame: 6 months

  11. Quality of Life (EQ-5D-5L)

    Instrument for Quality of life assessment: Euro Quality of Life - 5 Domain 5 Level (EQ-5D-5L). Value range: 0-100

    Time frame: 2 years

  12. Prescriptions

    Rates of prescription of preventative therapies

    Time frame: 5 years

  13. CTCA- incidental findings

    Number of participants with incidental findings from CTCA

    Time frame: Baseline

  14. CTCA related - radiation dose

    Radiation dose at baseline CTCA examination

    Time frame: Baseline

07

Study locations

2 sites
  • Department of Cardiology and Radiology, Rigshospitalet, The Heart Center, Capital Region of Copenhagen, University of Copenhagen
    Copenhagen, 2100, Denmark
  • The Copenhagen General Population Study, Herlev-Gentofte Hospital, University of Copenhagen, Denmark
    Herlev, 2730, Denmark
08

References and documents

Individual participant data

Plan to share: Yes — The intention is to share anonymised data with external collaborators and scientists in according to General Data Protection Regulation rules and Danish laws and regulations.

Supporting information: Study protocol, Clinical study report

Time frame: 1 year after publication of main results

Access criteria: Requests by email in 2030

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2027, 57 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 57 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2027, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2022
First posted
Jan 10, 2023
StartActual
Mar 20, 2023
Primary completionEst.
Dec 2027was Dec 2026
CompletionEst.
Jun 2033
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2026→Dec 2027
Nov 5, 2026
Sponsor
Rigshospitalet, Denmark→Copenhagen University Hospital, Rigshospitalet
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Dec 2026→Dec 2027
    Sponsor Rigshospitalet, Denmark→Copenhagen University Hospital, Rigshospitalet
    + 4 other changes: identifiers, verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05677386
Lead sponsor
Copenhagen University Hospital, Rigshospitalet
Responsible party
Klaus Fuglsang Kofoed (Principle Investigator, Copenhagen University Hospital, Rigshospitalet) — Principal investigator
First posted
Jan 10, 2023
Start date
Mar 20, 2023
Primary completion
Dec 2027 (estimated)
Completion
Jun 2033 (estimated)
Last update
Nov 5, 2026

Study contacts

Klaus F Kofoed, MD,SmSc
principal investigator · Copenhagen University Hospital, Rigshospitalet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion